Leelyn Smith LLC Has $2.27 Million Stake in Bristol Myers Squibb Company $BMY

Leelyn Smith LLC raised its position in Bristol Myers Squibb Company (NYSE:BMY) by 3.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 49,048 shares of the biopharmaceutical company’s stock after purchasing an additional 1,781 shares during the period. Leelyn Smith LLC’s holdings in Bristol Myers Squibb were worth $2,270,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the stock. Ranch Capital Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 4.4% during the 2nd quarter. Ranch Capital Advisors Inc. now owns 35,650 shares of the biopharmaceutical company’s stock valued at $1,650,000 after acquiring an additional 1,511 shares during the period. PKO Investment Management Joint Stock Co lifted its position in shares of Bristol Myers Squibb by 137.5% during the 2nd quarter. PKO Investment Management Joint Stock Co now owns 28,500 shares of the biopharmaceutical company’s stock valued at $1,319,000 after acquiring an additional 16,500 shares during the period. Keystone Financial Planning Inc. lifted its position in shares of Bristol Myers Squibb by 1.6% during the 2nd quarter. Keystone Financial Planning Inc. now owns 162,250 shares of the biopharmaceutical company’s stock valued at $7,511,000 after acquiring an additional 2,591 shares during the period. Sage Mountain Advisors LLC lifted its position in shares of Bristol Myers Squibb by 49.2% during the 2nd quarter. Sage Mountain Advisors LLC now owns 12,670 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 4,180 shares during the period. Finally, Washington Trust Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 8.9% during the 2nd quarter. Washington Trust Advisors Inc. now owns 4,875 shares of the biopharmaceutical company’s stock valued at $226,000 after acquiring an additional 400 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

BMY opened at $43.84 on Friday. The firm has a market cap of $89.24 billion, a P/E ratio of 17.68, a PEG ratio of 2.29 and a beta of 0.33. The firm has a 50-day moving average of $45.75 and a 200 day moving average of $47.14. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.7%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 100.00%.

Analyst Upgrades and Downgrades

A number of analysts have commented on BMY shares. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, October 13th. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research note on Tuesday, August 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Finally, Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $57.23.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.09% of the stock is owned by corporate insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.